Real-world analysis examines rituximab use in CAD
Treatment with rituximab led to improvements in biomarkers of red blood cell destruction among people with cold agglutinin disease (CAD), but the improvements often were short-lived and reversible, according to a real-world analysis in the U.S. The therapy, which often is used off-label for the rare autoimmune disease, also…